Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramBusiness Wire • 05/09/24
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramBusiness Wire • 05/09/24
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024Business Wire • 05/07/24
Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, AgainInvestors Business Daily • 04/25/24
Insights Into Gilead (GILD) Q1: Wall Street Projections for Key MetricsZacks Investment Research • 04/22/24
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024Business Wire • 04/08/24